.Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A02B_DrugsForPepticUlcerAndGastroOesophagealRefluxDis.A02BC03_Lansoprazole.Lansoprazole .Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A02B_DrugsForPepticUlcerAndGastroOesophagealRefluxDis.A02BC03_Lansoprazole.Lansoprazole| name: | Lansoprazole |
| ATC code: | A02BC03 | route: | oral |
| n-compartments | 2 |
Lansoprazole is a proton pump inhibitor (PPI) used to reduce gastric acid secretion. It is indicated for the treatment of gastroesophageal reflux disease (GERD), peptic ulcer disease, and Zollinger–Ellison syndrome. Lansoprazole is currently approved and widely used in clinical practice.
Pharmacokinetic parameters reported in healthy adult subjects, following single oral administration in fasting state.
Echizen, H (2016). The First-in-Class Potassium-Competitive Acid Blocker, Vonoprazan Fumarate: Pharmacokinetic and Pharmacodynamic Considerations. Clinical pharmacokinetics 55(4) 409–418. DOI:10.1007/s40262-015-0326-7 PUBMED:https://pubmed.ncbi.nlm.nih.gov/26369775
Yu, L, et al., & Zhang, Y (2023). Pharmacokinetics and Pharmacodynamics of Lansoprazole/Sodium Bicarbonate Immediate-release Capsules in Healthy Chinese Subjects: An Open, Randomized, Controlled, Crossover, Single-, and Multiple-dose Trial. Clinical pharmacology in drug development 12(9) 902–910. DOI:10.1002/cpdd.1251 PUBMED:https://pubmed.ncbi.nlm.nih.gov/37165834
Youssef, AF, et al., & Fort, FL (2003). Safety and pharmacokinetics of oral lansoprazole in preadolescent rats exposed from weaning through sexual maturity. Reproductive toxicology (Elmsford, N.Y.) 17(1) 109–116. DOI:10.1016/s0890-6238(02)00099-0 PUBMED:https://pubmed.ncbi.nlm.nih.gov/12507665